|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Membraneous beta-catenin expression was significantly reduced in both FAP (30%; 11-49) and sporadic (42%; 19-65) adenomas (normal controls 96%; 88-104), whereas marked nuclear staining occurred in sporadic, but not in FAP adenomas.
|
14986031 |
2004 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here, we focused our investigation on the beta-catenin gene which is implicated in colorectal carcinogenesis and tested whether beta-catenin mRNA is detectable in the plasma of colorectal carcinoma and adenoma patients using quantitative reverse transcriptase-PCR.
|
15014011 |
2004 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
No oncogenic beta-catenin mutations were identified in 34 MSI+ and 78 microsatellite stable (MSI-) sporadic colorectal cancers but a raised mutation frequency (8/44, 18.2%) was found in HNPCC cancers; this frequency was significantly higher than that in HNPCC adenomas (p=0.035) and in both MSI- (p<0.0001) and MSI+ (p=0.008) sporadic cancers.
|
15647192 |
2005 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The clinical, pathological, and immunophenotypic (hMLH1, hMSH2, MGMT, MIB-1, p53, and beta-catenin) properties of 28 mixed hyperplastic and adenomatous polyps of the colon (7 of which also contained carcinoma within the same lesion) were evaluated for the above immunopeptides in each of the different morphologic areas of the polyps, and the results were compared to traditional hyperplastic polyps, serrated adenomas, and conventional (nonserrated) adenomas.
|
15712188 |
2005 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We corroborated the Wnt/APC signalling pathway on the NT1 receptor promoter activation with human colon carcinogenesis, and showed that NT1 receptor gene activation was perfectly correlated with nuclear or cytoplasmic beta-catenin localization while NT1 receptor was absent when beta-catenin was localized at the cell-cell junction in early adenomas of patients with familial adenomatous polyposis, hereditary non-polyposis colorectal cancer and loss of heterozygosity tumours.
|
16299383 |
2006 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Subsequent Northern blotting, real-time reverse transcription-PCR, and in situ hybridization analysis confirmed their induction in beta-catenin-activated epithelial cells of murine adenomas.
|
16488993 |
2006 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In conclusion, the molecular and pathological classification of hepatocellular adenomas permits the identification of strong genotype-phenotype correlations and suggests that adenomas with beta-catenin activation have a higher risk of malignant transformation.
|
16496320 |
2006 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
BRAF and beta-catenin mutations were detected in 3 and 8% of the 101 flat-type adenomas, respectively.
|
17143260 |
2007 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We found that SHARP gene and protein expression is elevated in human colon and ovarian endometrioid adenocarcinomas and mouse colon adenomas and carcinomas carrying gene defects leading to beta-catenin dysregulation.
|
17234755 |
2007 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
However, nuclear beta-catenin expression was significantly greater in MCRA patients' tumours than in sporadic adenomas.
|
17505512 |
2007 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Activation of the Wnt pathway by conditionally deleting exon 3 of the beta-catenin gene at an early stage of enteroendocrine cell differentiation induced small-intestinal adenomas expressing serotonin, a feature not previously described in other tumors induced by Wnt in mice.
|
17592150 |
2007 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, cytoplasmic and/or nuclear accumulation of beta-catenin was observed in mutated adenomas by immunohistochemistry.
|
17854394 |
2008 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
No mutations or deletions were seen in exon 3 of the beta-catenin gene for either the adenomas or the carcinoma.
|
18246041 |
2008 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The TCF4-binding regions significantly correlate with Wnt-responsive gene expression profiles derived from primary human adenomas and often behave as beta-catenin/TCF4-dependent enhancers in transient reporter assays.
|
18268006 |
2008 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunohistochemical analysis of adenomas revealed increased nuclear beta-catenin accumulation in adenomas from Rassf1a(-/-); Apc(+/Min) mice, compared to those from Rassf1a(+/+); Apc(+/Min) mice, but no differences in proliferation marker (Ki67) staining patterns.
|
18391979 |
2008 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We report, for the first time, beta-catenin mutations in adenomas associated with PPNAD, further implicating Wnt-beta-catenin signalling in tumorigenesis linked to bilateral adrenal hyperplasias.
|
18419788 |
2008 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In CTNNB1 exon 3, we detected a stabilizing mutation (S37A) in 3 out of 20 analyzed adenomas.
|
18541010 |
2008 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
CXCL8 expression correlated with nuclear beta-catenin localization in epithelial cells of adenomas, but was associated with endothelial cells and neutrophils in the adenocarcinomas.
|
19173296 |
2009 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A strong topographical correlation was noted between human defensin 5 expression and nuclear beta-catenin expression in conventional adenomas and in conventional dysplastic epithelium of mixed polyps.
|
19269007 |
2009 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
These findings suggest that, following APC loss, CtBP1 contributes to adenoma initiation as a first step, whereas KRAS activation and beta-catenin nuclear localization promote adenoma progression to carcinomas as a second step.
|
19450512 |
2009 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
An advanced invasive non-functioning adrenocortical carcinoma carried a somatic heterozygous BRAF V600E mutation, while 4 functioning and 4 non-functioning adenomas and 3 functioning carcinomas carried different CTNNB1 activating mutations.
|
19498322 |
2009 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Sequencing of genomic DNA extracted from a subset of hyperplastic polyps, SSAs, SSAs with dysplasia, TSAs and tubular adenomas failed to identify any CTNNB1 mutations to account for abnormal beta-catenin nuclear labeling.
|
19745699 |
2009 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunostaining of beta-catenin was performed in all carcinomas and in 66 adenomas (including three atypical).
|
19755524 |
2010 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, we found that adenomas bearing truncated Apc had increased beta-catenin activity when compared with tumors lacking Apc protein, which could lead to context-dependent inhibition of tumorigenesis.
|
20010873 |
2010 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Increased cytoplasmic and/or nuclear beta-catenin staining was seen in 94% and 80% of the adenomas. beta-Catenin nuclear staining was strongly associated with MYC levels (p value 0.03) but not with KRAS mutations.Copy number aberrations were rare.
|
20196079 |
2010 |